Metformin-induced metabolic reprogramming of chemoresistant ALDHbright breast cancer cells by M. Cioce et al.
Oncotarget4129www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/ Oncotarget, Vol. 5, No. 12
Metformin-induced metabolic reprogramming of chemoresistant 
ALDHbright breast cancer cells
Mario Cioce1,*, MariaCristina Valerio2,*, Luca Casadei2, Claudio Pulito3, Andrea 
Sacconi4, Federica Mori3, Francesca Biagioni4, Cesare Manetti2, Paola Muti5, 
Sabrina Strano3, and Giovanni Blandino4
1 Department of Cardiothoracic Surgery, NYU Langone Medical Center, New York, NY USA 
2 Department of Chemistry, University of Rome ‘La Sapienza’, Rome, Italy
3 Molecular Chemoprevention Group, Italian National Cancer Institute “Regina Elena”, Rome, Italy
4 Translational Oncogenomic Unit, Italian National Cancer Institute “Regina Elena”, Rome, Italy
5 Department of Oncology, McMaster University, Hamilton, Ontario, Canada
* These two authors contributed equally
Correspondence to: Giovanni Blandino , email: blandino@ifo.it
Keywords: Metformin, metabolism, chemoresistance, ALDH, metabolic reprogramming, cancer
Received:  January 22, 2014 Accepted: March 24, 2014 Published: March 26, 2014
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, 
distribution, and reproduction in any medium, provided the original author and source are credited. 
ABSTRACT:
Metabolic remodeling is a hallmark of cancer progression and may affect tumor 
chemoresistance. Here we investigated by 1H-NMR/PCA analysis the metabolic 
profile of chemoresistant breast cancer cell subpopulations (ALDHbright cells) and 
their response to metformin, a promising anticancer metabolic modulator. The 
purified ALDHbright cells exhibited a different metabolic profile as compared to their 
chemosensitive ALDHlow counterparts. Metformin treatment strongly affected the 
metabolism of the ALDHbright cells thereby affecting, among the others, the glutathione 
metabolism, whose upregulation is a feature of progenitor-like, chemoresistant cell 
subpopulations. Globally, metformin treatment reduced the differences between 
ALDHbright and ALDHlow cells, making the former more similar to the latter. Metformin 
broadly modulated microRNAs in the ALDHbright cells, with a large fraction of them 
predicted to target the same metabolic pathways experimentally identified by 1H-NMR. 
Additionally, metformin modulated the levels of c-MYC and IRS-2, and this correlated 
with changes of the microRNA-33a levels. In summary, we observed, both by 1H-NMR 
and microRNA expression studies, that metformin treatment reduced the differences 
between the chemoresistant ALDHbright cells and the chemosensitive ALDHlow cells. 
This works adds on the potential therapeutic relevance of metformin and shows the 
potential for metabolic reprogramming to modulate cancer chemoresistance.
INTRODUCTION
It appears increasingly clear that the stable 
acquisition of a cancer phenotype involves metabolic 
remodeling. This echoes the pioneering studies from Otto 
Warburg and can be achieved through redirecting glucose 
and non glucose-dependent pathways toward anabolic 
generation of macromolecules, a crucial requirement 
for cancer cells[1, 2]. As a proof of this, multilayered 
modulation of metabolic enzymes by known oncogenes 
and tumor suppressors has been recently unveiled, with 
more detailed data available regarding the c-MYC-
mediated modulation of glycolysis and glutamine 
metabolism in cancer cells [3]. Resistance to therapy 
is an inherent part of the pro-tumorigenic program 
and, almost invariably, an adverse prognostic factor 
for solid and non-solid tumors. Emergence within the 
tumor mass, of distinct chemoresistant cell populations 
has been recognized as an important mechanism for 
chemoresistance, hence tumor relapse. We and others 
have characterized chemoresistant cell subpopulations 
from breast and mesothelioma cell lines and shown that 
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those cells are endowed with Epithelial-To-Mesenchymal 
(EMT) features, exhibit a precursor-like phenotype 
and possess high levels of Aldehyde Dehydrogenase 
(ALDH) activity [4, 5]. ALDH belongs to a class of 
detoxifying enzymes whose expression is linked to cancer 
chemoresistance [6, 7] and, by virtue of those high levels 
of ALDH activity, chemoresistant cell subpopulations 
can be tracked by FACS (ALDHbright cells). We and others 
have shown that breast, ALDHbright-enriched cancer cell 
subpopulations are resistant in vitro to campthotecin, 
cisplatin, etoposide, topotecan [5] and docetaxel (in 
vivo) [8]. Tanei et al have reported that ALDH1+ cells 
are increased in a group of 78 breast cancer patients after 
neoadjuvant chemotherapy [9] and such phenomenon 
has been shown to occur in early passage colon cancer 
xenograft tumors as well [10]. Consequently, ALDH 
expression can be an important prognostic factor [6, 
11]. Little is known regarding the metabolic features 
of the ALDHbright chemoresistant cell subpopulations. 
Here we explore which are the metabolic features of 
the chemoresistant ALDHbright cells and whether their 
metabolic characteristics reflect their functional properties. 
This may add precious knowledge to the mechanisms of 
tumor relapse and its modulation, to achieve anticancer 
effects. With regard to this latter point, metformin, an 
oral anti-diabetic biguanide, has been shown to target 
chemoresistant putative cancer stem cells from a variety 
of solid tumors, including lung, prostate, ovary cancer and 
glioma [12-14]. We and others have shown that metformin 
interferes with tumor engraftment and synergizes with 
chemotherapy in mouse xenografts, with both effects that 
suggest the targeting of chemoresistant, tumor initiating 
cell populations within the tumor mass. Additionally, we 
have shown a metabolic anticancer effect of metformin on 
unfractionated breast cancer cells lines which is partially 
dependent on DICER-mediated microRNA modulation 
[15]. However, to our knowledge, no studies have detailed 
the effect of metformin on purified chemoresistant cells 
in terms of metabolic modulation and microRNA 
modulation, in particular whether the metabolic effect of 
metformin are similar or different from those we described 
on unfractionated cell populations. Thus, here we studied 
the metabolic features of ALDHbright cells isolated from 
three histologically different breast cancer cell lines. We 
first show that ALDHbright cells are metabolically different 
from ALDHlow cells. Subsequently, we describe how 
metformin treatment affects ALDHbright cell metabolism 
by reducing the differences between the chemoresistant 
ALDHbright and the chemosensitive ALDHlow cells through 
targeting pyruvate metabolism, glycolysis, glutathione 
metabolism, pentose phosphate pathway, HIF-1α and the 
insulin signalling pathways. Additionally, we show that 
metformin treatment largely modulated the microRNA 
expression profile of ALDHbright cells and did so by 
broadly modulating microRNAs predicted to impinge on 
cell metabolism and to target the mentioned pathways. 
Finally, we show that metformin modulated master cancer 
metabolic modulators such as c-MYC and IRS2 in the 
ALDHbright cells and this correlated with modulation of 
the microRNA-33a which is known to target both the 
abovementioned factors. We believe this study adds on 
what is known on the anticancer metabolic actions of 
metformin and further provides a rationale for its potential 
use combined with chemotherapy to prevent tumor 
relapse, through targeting of chemoresistant, residual cell 
subpopulations.
RESULTS
FACS-based isolation of breast cancer ALDHbright 
and ALDHlow cells (Fig.1). 
We determined by FACS the percentage of cells 
endowed with high ALDH activity (ALDHbright cells) 
from MCF-7, BT-474 and SUM-159 cell lines. ALDH 
enzymatic activity was detected by following the 
accumulation of a fluorescent ALDH substrate, with 
the mean fluorescence of cells pretreated with a known 
inhibitor of the ALDH activity (DEAB) set as background 
(Fig 1A-B). We found that all the breast cancer cell lines 
in our collection contained readily detectable ALDHbright 
cells, although with some variability among each cell 
line. Given the involvement of the ALDHbright cells in 
mediating cancer chemoresistance, we treated MCF-7, 
BT-474 and SUM159 cells with cisplatin and doxorubicin, 
two commonly used chemotherapy agents for breast 
cancer and we evaluated the percentage of ALDHbright 
cells among the surviving cell populations. We found 
that, upon chronic treatment with cisplatin (40µM, 72hrs) 
or doxorubicin (0.1µM, 72hrs) the percentage of breast 
cancer ALDHbright cells increased in BT-474 and SUM-159 
cells and remained unchanged or only slightly decreased 
in the MCF-7 cells (Fig. 1A-B and Suppl. Fig.1). 
Interestingly, a barely detectable number of ALDHbright 
cells was found in the dysplastic, non-transformed breast 
cells MCF10A (1.4 ± 0.4 %)(Fig.1B and Suppl. Fig.1). 
This is in agreement with previous work [5]. However, 
the MCF-10A ALDHbright cells became undetectable upon 
cisplatin and doxorubicin treatment (Fig.1B and Suppl. 
Fig.1), in agreement with the chemosensitivity of the cell 
line[16]. Clonogenic assays with FACS-purified ALDHbright 
and ALDHlow cells confirmed that the ALDHbright cells in 
the transformed breast cancer cell lines represented the 
main chemoresistant cell subpopulation as compared to 
the ALDHlow cells (the latter representing most of the 
cells in unsorted cell lines) (Fig. 1C-D). The availability 
of the described experimental system prompted us to 
characterize the metabolic profile of the purified ALDHbright 
chemoresistant cell subpopulations. 
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The metabolic profile of ALDHbright cells is 
different from that of ALDHlow cells (Fig. 2).
The conditioned media from FACS sorted 
ALDHbright and ALDHlow MCF-7, BT-474 and SUM-159 
cells, were analysed using 1H-NMR spectroscopy. NMR 
profiles identified at the beginning of observation were 
compared to those representing the end of the experiment 
(after 24 hours). In this way the resulting positive net 
balances indicated release or production of metabolites, 
whereas negative net balances indicated uptake or 
consumption of metabolites. We analyzed the NMR data 
by using Principal Component Analysis (PCA) carried 
out on untreated samples. This unsupervised method 
allows orthogonal decomposition of variance associated 
with the analyzed metabolites. Six components (PC 
1-6) were sufficient to explain 65% of total variability 
of the system. In Fig. 2A, the PC1 (the most important 
metabolic component explaining 21% of total variance 
of the samples) and PC2 (the second most important 
metabolic component explaining 13% of total variance 
of the samples) discriminated between the conditioned 
media of the BT-474, MCF-7 and SUM-159 cell lines. 
Being the three breast cancer cell lines histologically and 
biologically very different, this was partially expected. 
To a minor extent, the PC1/PC2 plane was also capable 
of discriminating the subpopulation state (ALDHbright or 
ALDHlow). To detail more the previous observations we 
carried out an ANOVA test on the component scores 
relative to the BT-474, MCF-7 and SUM-159 samples by 
establishing, as sources of variation, the cell subpopulation 
(ALDHbright and ALDHlow cells) and the cell line (MCF-
7, BT-474 and SUM-159) (Suppl. Table 1).This analysis 
showed that the cell line differences acted as a major 
Fig.1: Breast  cancer ALDHbright cells are chemoresistant. A. Representative FACS dot plots of SUM-159 cells assayed for 
Aldhehyde Dehydrogenase (ALDH) activity. Cells enriched for ALDH activity (ALDHbright) were gated (red-r1). To set the background, 
the percentage of ALDHbright cells was determined  in the presence of DEAB, an inhibitor of the ALDH enzyme (upper left plot). B. 
Histogram showing the percentage of ALDHbright cells in the indicated cell lines treated with vehicle, cisplatin or doxorubicin for 72hrs. 
Mean ± SE values of two independent experiments were reported. NS: not significant. *: p<0.05 (when compared to vehicle-treated 
samples). Additional representative dot plots relative to the graph in 1B are available in Suppl. Fig. 1. C. Clonogenic assay. Representative 
micrographs of the colonies formed by SUM-159 cells pulsed with vehicle, cisplatin and doxorubicin for 16hrs and seeded at clonal density. 
Colonies stained with crystal violet 9 days later. D. Histogram showing the absolute number of colonies formed by the indicated cell 
lines treated as in 1C. Please note that the untransformed MCF-10A were not assayed  because non clonogenic. Mean ± SE values of two 
independent experiments were reported. *: p<0.05 (as compared to ALDHbright cells). 
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factor affecting the distribution of the samples (F statistics 
= 98.42 and 432.77 for PC1 and PC2, respectively). 
However, the difference among the cell subpopulations 
(ALDHbright vs ALDHlow) common to all cell lines was 
detectable by the PC1 and PC4 components (F statistics 
= 35.54 and 28.08 for PC1 and PC4, respectively). The 
ALDHbright vs ALDHlow difference, cell line dependent, was 
detectable by the PC1 and PC3 components (F statistics 
= 20.76 and 18.39 for PC1 and PC3, respectively). The 
detectable impact of the ALDHbright vs ALDHlow condition 
on the whole metabolic profile of the samples analyzed 
prompted us to exclude the major effect of the cell line 
and to focus on the differences between ALDHbright and 
ALDHlow cell samples by using the orthogonal projections 
to latent structures-discriminant analysis (OPLS-DA) (Fig. 
2B). The OPLS-DA model generated one Latent Variable 
(LV) that explained 55% of the X-variance and 100% of 
Y-variance with a cumulative predicted fraction of the 
joint X and Y variation of 85%. A clear separation between 
the ALDHlow and ALDHbright populations was found in 
the first component (LV1) independently from cell type 
(while the metabolic difference between the cell lines 
were observed on LV0) (Fig. 2B). From the analysis of the 
O-PLS-DA loadings we observed that 3-hydroxy-butyrate, 
alanine, lactate, acetate, succinate, glucose and formate 
were the main discriminatory metabolites responsible 
for the difference between ALDHbright and ALDHlow cell 
subpopulations (Table 1).
Metformin-induced changes in the metabolic 
phenotype of ALDHbright and ALDHlow cells (Fig. 
3). 
Next, we tested the effect of metformin on the 
metabolic processes of the ALDHbright and ALDHlow 
cell subpopulations. More specifically, we detailed the 
1H-NMR profile of the conditioned media from the 
ALDHbright and ALDHlow subpopulations of BT-474, MCF-
7 and SUM-159 cells treated with vehicle (PBS1X) or 
metformin at a non cytotoxic concentration/length of 
treatment combination (0.5mM-24hrs) (Suppl. Fig. 2). 
This was done to avoid interference of apoptotic processes 
with the 1H-NMR analysis.
PCA analysis of the vehicle- and metformin- 
treated ALDHbright and ALDHlow cells from all three breast 
cancer cell lines was very complex and revealed, again, a 
predominant effect of the differences among the parental 
cell lines (thus masking the effect of metformin treatment)
(Suppl. Table 2). Therefore, we analyzed the effect of 
metformin treatment on the ALDHbright and ALDHlow cell 
subpopulations for each cell line independently. The PCA 
results for each dataset are depicted in Figure 3A-C, where 
the score plots for the first two model components are 
shown. A clear separation among control and metformin-
treated samples for each subpopulation was obtained. This 
revealed that the PC1 (for the BT-474 and SUM-159 cells), 
and the PC2 (for the MCF-7) were mainly responsible 
for the differences between vehicle- and metformin-
Figure 2: A-B ALDHbright and ALDHlow cells are metabolically distinguishable cell subpopulations. Overview of the PCA 
(A) and OPLS-DA (B) models built on the NMR datasets of medium samples collected from ALDHlow (open) and ALDHbright (filled) 
populations of MCF-7 (triangle), BT-474 (square) and SUM-159 (circle) cell lines. A. The obtained PCA model of ALDH subpopulations 
was dominated by the effect of cell line differences acting as major order parameter: PC1 and PC2 components are mainly responsible for 
among cell lines differences (see also Table 1). B. OPLS-DA analysis of the same samples as from A shows a clear separation between the 
ALDHlow and ALDHbright populations, independently from cell type, was found in the first component.
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Table 1: Metabolites contributing to the difference between ALDHbright and ALDHlow, 
determined by the analysis of O-PLS-DA loadings. 
Metabolite ALDHbright vs. ALDHlow* Related KEGG Pathway Maps**
3-Hydroxy-butyrate High (p) Synthesis and degradation of ketone bodies
Alanine High (p) Alanine, aspartate and glutamate metabolism
Lactate High (p) Glycolysis/GluconogenesisPyruvate metabolism
Acetate Low (p)
Glycolysis/Gluconogenesis 
Pyruvate metabolism
Succinate Low (c)
Citrate cycle (TCA cycle)
Oxidative phosphorylation
Alanine, aspartate and glutamate metabolism
Tyrosine metabolism
Phenylalanine metabolism
Carbon metabolism
Glucose Low (c)
Glycolysis/Gluconogenesis
Pentose phosphate pathway
Amino sugar and nucleotide sugar 
metabolism
HIF-1 signaling pathway
Insulin signaling pathway
Formate High (p) Pyruvate metabolism
Carbon metabolism
*“High” indicates that the metabolite was at a higher concentration in medium samples from 
ALDHbright cells; “Low” indicates that the metabolite was at a lower concentration in medium 
samples from ALDHbright cells; “c” and “p” for each metabolite indicate consumption or production, 
respectively.
** The metabolites are mapped to their respective biochemical pathways as delineated in the 
Kyoto Encyclopedia of Genes and Genomes (Release 69.0, January 1, 2014; KEGG, http://www.
genome.jp/kegg).
Figure 3A-C: PCA analysis of vehicle- and metformin-treated ALDHbright and ALDHlow cells. PCA models built on the NMR 
datasets of medium samples collected from ALDHlow (red) and ALDHbright (black) subpopulations of vehicle- (open) and metformin-treated 
(filled) MCF-7 (triangle), BT-474 (square) and SUM-159(circle) cells). Please note that filled samples (metformin-treated cells) occupy a 
very similar location in the component space. In each line, the Euclidean distance (arrows) between the centroids (stars) of the two treated 
subpopulations is smaller than the distance between the treated ALDHlow and untreated ALDHbright cells, suggesting that the metabolism of 
ALDHbright and ALDHlow cells became more similar upon metformin treatment.
Oncotarget4134www.impactjournals.com/oncotarget
treated ALDHbright and ALDHlow cell subpopulations. 
The quantitative PCA approach revealed that, when 
considering the same metabolic process for both cell 
subpopulations, the effects of metformin were more 
evident in the ALDHbright as compared to the ALDHlow cells. 
The maximum difference between the metformin- and 
vehicle-treated groups (thus, the maximum drug effect) 
was observed for the BT-474 and SUM-159 ALDHbright 
cells on the PC1 and for the MCF-7 ALDHbright cells on the 
PC2 (Suppl. Table 3). Notably, we found that the treatment 
with metformin reduced the difference between ALDHbright 
and ALDHlow cells. More specifically, we found that, for 
each cell line, the Euclidean distance (arrows) between 
the centroids (i.e, the barycenter of the group of samples)
(stars) (Fig. 3A-C) of the treated ALDHlow and ALDHbright 
samples was smaller than the distance between the treated 
ALDHlow and the untreated ALDHbright samples, suggesting 
that Metformin changed the metabolism of ALDHbright 
towards a phenotype more similar to that of metformin-
treated ALDHlow cells This was very evident for the SUM-
159 cell line. 
Metabolomic signatures of Metformin treated 
ALDHbright cells (Fig. 4). 
Next, we detailed the metabolic profiles relative to 
the vehicle- and metformin- treated ALDHbright cells (Fig. 
4A-E). For each cell line, the PCA produced solutions with 
two significant components, explaining about 52%, 65% 
and 47% of the total variability of the system for the MCF-
7, BT-474, and SUM-159 cells, respectively (data not 
shown). This highlighted significant differences between 
the two groups on the PC1. Additionally, despite some 
differences between the cell lines, we observed similarities 
in the correlation patterns of metabolite loadings (Fig. 
4A-E). For each cell line, the PC1 included the following 
variables with the highest correlation levels: glutamine 
and glucose consumption and pyroglutamate production 
with positive loadings as well as lactate production with 
negative loadings. Therefore, the PC1 analysis indicated 
that metformin treatment induced higher consumption 
of glutamine and glucose as well as higher production 
of lactate (positive correlation with PC1) compared to 
untreated cells (Fig. 4C-E). 
The negative correlation between glutamine and 
glucose consumption and lactate production in the 
Figure 4: A-F: Metabolomic analysis of metformin treated ALDHbright cells. Upper panels. Overview of the PCA model 
built on the NMR dataset of media samples of control (open) and metformin-treated (filled) ALDHbright cells from MCF-7 (triangle), 
BT-474 (square) and SUM-159 (circle) cells. The score and loading plots of the first two components (PC1 versus PC2) are shown 
superimposed. The score plot shows the differentiation between untreated and metformin-treated samples, while the loading plot highlights 
which metabolites are responsible in separating control and metformin-treated samples. Lower panels.  Histograms indicate the relative 
levels of the metabolites considered in the score/loading plots for MCF-7 (right), BT-474 (middle) and SUM-159 (left). Loading values are 
represented using the abbreviation of metabolites: leucine, Leu; valine, Val; 3-Methyl-2-oxovalerate, 3M-2OV; 3-hydroxy-butyrate, 3-HB; 
lactate, Lac; alanine, Ala; acetate, Ac; methionine, Met; glutamine, Gln; glutamate, glu; pyruvate, Pyr; pyroglutamate, Pyroglu; 2-Oxo-4-
methylvalerate, 2O-4MV; glucose, Glc; histidine, His, phenylalanine, Phe ;formate, For.
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loading plots of the ALDHbright cells from all the analysed 
cell lines suggested higher fluxes through glycolysis or 
glutaminolysis in the treated cells compared to untreated 
controls. Previous studies using NMR analysis with 
[1,2-13C]-glucose revealed that, in metformin-treated cells, 
lactate is more produced from glutaminolysis rather than 
from glycolysis therefore suggesting that the net effect of 
metformin consists of a reduction of the glycolytic flux. 
A lower production of pyroglutamate upon metformin 
treatment was also observed (negative correlation with 
PC1). A lower excretion of pyroglutamate suggested 
a reduced level of intracellular glutathione. In facts, 
pyroglutamate, also known as 5-oxoproline, is converted 
to glutamate by 5-Oxoprolinase. As glutamate is required 
in the first step of GSH synthesis, the lower production of 
pyroglutamate observed in treated cells suggest a minor 
level of intracellular glutathione. Moreover, in MCF-7 and 
BT-474 cell lines, we observed that glucose and glutamine 
consumption correlated also with the production of 
alanine (opposite loadings) suggesting a higher activation 
of alanine aminotransferases in the metformin-treated 
cells. However, the fact that acetate was a strong negative 
loader on PC1 for BT-474, demonstrated that the alanine 
aminotransferase pathway was also used to provide 
precursors needed for fatty acid synthesis. Nevertheless, 
the higher excretion of acetate into media of the 
metformin-treated cells reflected the smaller availability 
of acetyl-CoA units for fatty acid synthesis. For the MCF-
7 and BT-474 cells, the negative correlation of 3-methyl-
2-oxovalerate and 2-oxo-4-methylvalerate loadings within 
the metformin-treated cells as opposed to the control-
treated cells indicated a higher metabolic flux through the 
branched-chain amino acid aminotransferase pathway. 
This strongly suggests the use of branched amino acids 
for energy production instead of its use for macromolecule 
biosynthesis in the metformin-treated cells. Analysis of the 
identified metabolites with the KEEG pathways indicated 
that, in all three ALDHbright cell subpopulations treated with 
metformin, we observed perturbations of the glycolysis, 
pyruvate metabolism, glutathione metabolism, purine and 
pyrimidine metabolism, alanine, aspartate, glutamate, 
arginine and proline metabolism , pentose phosphate 
pathway, amino sugar and nucleotide sugar metabolism, 
HIF-1α and the insulin signalling pathways in all cell lines 
(Table 2). 
Metformin-mediated modulation of microRNAs 
sustains its metabolic effects on the ALDHbright cells (Fig. 5 
and 6). We previously demonstrated that metformin exerts 
anticancer metabolic effect on unsorted breast cancer 
cell populations by broadly modulating the metabolic 
pathways, at least partially in a DICER-dependent 
microRNA modulation[15]. We verified whether a similar 
mechanism would take place in the sorted ALDHbright 
cells and whether this may explain the metabolic changes 
observed in the treated cells. Therefore, we analysed the 
microRNA expression profile of vehicle- and metformin- 
treated, FACS sorted ALDHbright cells (Fig. 5). This first 
revealed that, at steady state, the microRNA expression 
profile of ALDHlow and ALDHbright was very different, 
mirroring the observed difference in their metabolic 
Table 2: Metabolic pathways perturbed by Metformin in all the analyzed breast cancer cell lines.
Metabolite Metformin vs. control* Related KEGG Pathway Maps**
Lactate High (p)
Glycolysis/Gluconogenesis
Pyruvate metabolism
Pyroglutamate Low (p) Glutathione metabolism
Glutamine Low (c)
Purine metabolism
Pyrimidine metabolism
Alanine, aspartate and glutamate metabolism
Arginine and Proline metabolism
Glucose Low (c)
Glycolysis/Gluconogenesis
Pentose phosphate pathway
Amino sugar and nucleotide sugar metabolism
HIF-1 signaling pathway
Insulin signaling pathway
*“High” indicates that the metabolite was at a higher concentration in medium samples from metformin-
treated cells; “Low” indicates that the metabolite was at a lower concentration in medium samples from 
metformin-treated cells; “c” and “p” for each metabolite indicate consumption or production, respectively.
** The metabolites are mapped to their respective biochemical pathways as delineated in the Kyoto 
Encyclopedia of Genes and Genomes (Release 69.0, January 1, 2014; KEGG, http://www.genome.jp/
kegg).
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profile. In facts, the unsupervised PCA analysis of 497 
expressed microRNAs in the ALDHlow and ALDHbright 
cell subpopulations revealed a clear separation of the two 
cell subpopulations on both the PC1 and the PC2 (61.5% 
and 18.1% of the total variance, respectively)(Fig.5A). 
Next, we evaluated the microRNA expression profile of 
vehicle- and metformin- treated ALDHbright and ALDHlow 
cells derived from the SUM-159 cells. This provided us 
with two observations: first, metformin treatment induced 
changes in microRNA expression levels in both ALDH 
bright and ALDHlow cells (Fig.5B), with a slightly more 
evident effect on the ALDHbright cells; second, metformin 
treatment reduced the distance in the microRNA 
expression profile between ALDHbright and ALDHlow cells 
(Fig. 5B). This was reminiscent of the metabolic effects 
of the drug on the ALDHbright and ALDHlow cells, which 
were consistent with the acquisition of a more similar 
metabolic profile between the two cell subpopulations. 
Altogether, these observations suggest that metformin 
treatment of breast cancer ALDHbright cells partially 
reverted a chemoresistant and clonogenic phenotype 
to a chemosensitive, more differentiated one. In order 
to support this observation, we detailed the microRNA 
modulation in the metformin treated-ALDHbright cells 
(Fig.6A) Interestingly, a large fraction (89/125) of the 
microRNAs significantly modulated in the metformin-
treated ALDHbright cells (Suppl. Table 4) was predicted to 
target metabolic pathways (Table 3) and caused a strong 
Figure 5: A. ALDHbright and ALDHlow cells differ in their microRNA expression profile. PCA of the microRNA expression profile of 
the untreated ALDHbright and ALDHlow cell subpopulations derived from the SUM-159 cells (497 microRNAs expressed/analyzed). B. 
Metformin modulates microRNAs in the ALDHbright and ALDHlow cells. PCA of 125 miRNAs modulated by metformin in ALDHbright and 
ALDHlow SUM-159 cells. Principal Component Analysis. Percentage of the explained variance is indicated for the first two components.
Figure 6: Metformin modulates microRNAs associated with metabolic functions in the ALDHbright cells. A. PCA of 89 
miRNAs modulated by metformin and involved in metabolic pathways in SUM-159 cells. Principal Component Analysis. Percentages of 
the explained variance is indicated for the first two components. B. Heat Map of 89 miRNAs modulated by metformin and involved in 
metabolic pathways. Unsupervised Hierarchical Clustering. Red indicates higher expression and green lower expression of the indicated 
miRNAs for each sample. The list of the 89 microRNAs used for the heat map can be found in Suppl. Table 4.
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separation of the samples on the PC1 (Fig. 6A) We found 
that the pathways found deregulated by metformin in the 
1H-NMR studies were represented within those predicted 
by the microRNA analysis, thus establishing a correlation 
between the effect of metformin on the microRNAs and its 
metabolic activity(Table 3). 
Metformin targets c-MYC and IRS-2 via mir-
33a modulation (Fig. 7). We and others have recently 
demonstrated that the anticancer metabolic activity of 
metformin toward unsorted breast cancer cells is partially 
insulin pathway
miR-335-5p,miR-124-3p,miR-98,miR-16-5p,miR-155-5p,miR-26b-5p,miR-1,miR-7-
5p,miR-21-5p,let-7b-5p,miR-192-5p,miR-128,miR-148b-3p,miR-375,miR-30a-5p,miR-
130b-3p,miR-125a-5p,miR-103a-3p,miR-93-5p,miR-10a-5p,miR-34a-5p,miR-24-3p,miR-
19b-3p,miR-193b-3p,miR-122-5p,miR-186-5p,let-7,miR-126-3p,miR-181a-5p,miR-29c-
3p,miR-101-3p,miR-141-3p,miR-145-5p,miR-214-3p,miR-590-3p,miR-33a-5p,miR-769-
5p,miR-200a-3p,miR-32-5p,miR-132-3p,miR-27a-3p,miR-149-3p,miR-217,miR-200c-
3p,mir-199a,miR-615-3p,mir-199a*,miR-22-3p,miR-374b-5p,miR-429,miR-9-5p,miR-140-
3p,miR-18a-5p,miR-200b-3p,miR-421,miR-96-5p'
alanine aspartame 
metabolism
'miR-335-5p,miR-155-5p,miR-16-5p,miR-26b-5p,miR-34a-5p,miR-192-5p,miR-128,miR-
24-3p,miR-27a-3p,miR-21-5p,miR-1,miR-124-3p,miR-590-3p,miR-101-3p,miR-96-
-5p,miR-186-5p,miR-30b-5p,miR-7-5p,miR-183-5p,miR-98,miR-32-5p'
amino sugar metabolism
'miR-26b-5p,miR-124-3p,miR-155-5p,miR-30a-5p,miR-375,miR-30b-5p,miR-1,miR-
34a-5p,miR-335-5p,miR-106b-5p,mir-30,miR-98,miR-16-5p,miR-32-5p,miR-9-5p,let-
-7b-5p,mir-199a,miR-21-5p,miR-101-3p,miR-193b-3p,miR-128,miR-590-3p,miR-24-
3p,miR-192-5p,miR-148b-3p,miR-122-5p'
Aminoacyl-trna biosinthesis 'miR-16-5p,miR-155-5p,miR-26b-5p,let-7b-5p,miR-30a-5p,miR-93-5p,miR-101-3p,miR-124-3p,miR-19b-3p,miR-192-5p,miR-1,miR-21-5p,miR-98,miR-130b-3p'
cysteine metabolism
'miR-26b-5p,miR-375,miR-193b-3p,miR-155-5p,miR-335-5p,miR-29b-3p,let-7b-5p,miR-
29c-3p,miR-369-5p,miR-34a-5p,miR-29a-3p,miR-16-5p,miR-33a-5p,miR-191-5p,mir-
199a,mir-30,miR-186-5p,miR-548b-3p,miR-30a-5p,miR-152,let-7d-5p,miR-106b-5p,mir-
148,miR-1,miR-148b-3p,miR-7-5p,miR-192-5p,miR-124-3p'
D-glutamine and glutamate 'miR-335-5p,miR-7-5p'
glycolisis
'miR-335-5p,miR-124-3p,miR-155-5p,miR-30a-5p,mir-17-92,miR-375,miR-34a-5p,miR-
1,miR-7-5p,miR-16-5p,miR-26b-5p,mir-199a,miR-122-5p,mir-30,miR-148b-3p,let-7b-
5p,miR-98,miR-24-3p,miR-22-3p,miR-132-3p,miR-145-5p,miR-133b,miR-192-5p,miR-
181a-5p,miR-33a-5p,miR-133a,miR-27a-3p,miR-128,miR-9-5p'
pentose phospate pathway 'miR-124-3p,miR-335-5p,miR-1,miR-26b-5p,miR-148b-3p,miR-375,miR-34a-5p,edited-hsa-mir-376a-5p,mir-1b,let-7b-5p,miR-192-5p,mir-30,miR-142-3p,miR-30a-5p,miR-373-3p'
Pyruvate metabolism
'miR-335-5p,miR-34a-5p,miR-155-5p,miR-26b-5p,let-7b-5p,miR-16-5p,miR-30a-5p,miR-
124-3p,miR-24-3p,miR-7-5p,miR-1,miR-33a-5p,miR-133b,miR-27a-3p,miR-375,miR-
133a,miR-21-5p,miR-22-3p,miR-122-5p,miR-23b-3p,miR-193b-3p,miR-148b-3p,miR-
98,miR-192-5p,miR-181a-5p'
'purine'metabolism
'miR-124-3p,miR-335-5p,let-7b-5p,miR-26b-5p,miR-98,miR-155-5p,miR-30a-5p,miR-
1,miR-16-5p,miR-193b-3p,miR-7-5p,miR-34a-5p,miR-192-5p,mir-30,miR-24-3p,miR-96-
5p,miR-128,miR-375,miR-19b-3p,miR-21-5p,miR-103a-3p,miR-196a-5p,miR-148b-3p,let-
7d-5p,miR-142-3p,miR-93-5p,miR-133b,miR-186-5p,edited-hsa-mir-376a-5p,miR-130b-
3p,miR-133a,miR-9-5p,miR-421,miR-122-5p,mir-132/mir-212,miR-340-5p,miR-18a-5p'
'pyrimidine' metabolism
'miR-26b-5p,let-7b-5p,miR-34a-5p,miR-124-3p,miR-155-5p,miR-193b-3p,miR-192-
5p,miR-1,miR-7-5p,miR-335-5p,miR-30a-5p,miR-16-5p,miR-24-3p,miR-98,mir-30,miR-
186-5p,miR-148b-3p,miR-375,miR-21-5p,miR-196a-5p,miR-101-3p,miR-128,miR-103a-
3p,miR-142-3p,miR-122-5p,miR-421,miR-9-5p,miR-10a-5p,mir-199a*,miR-96-5p,miR-
590-3p,let-7d-5p,mir-132/mir-212,miR-374b-5p'
Sinthesis of ketone Bodies 'miR-21-5p,miR-192-5p,miR-18a-5p,miR-1,miR-335-5p,miR-23b-3p,miR-155-5p,miR-19b-3p,miR-26b-5p,miR-186-5p,miR-375,miR-124-3p,miR-96-5p'
'valine' metabolism
'miR-124-3p,miR-26b-5p,miR-192-5p,miR-1,miR-155-5p,miR-34a-5p,miR-335-5p,miR-16-
5p,miR-32-5p,miR-193b-3p,miR-21-5p,miR-9-5p,miR-19b-3p,miR-128,let-7b-5p,miR-186-
5p,miR-96-5p,miR-7-5p,miR-18a-5p,miR-27a-3p,miR-23b-3p'
Table 3: Main metabolic functions predicted to be modulated by  the metformin-regulated microRNAs.
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Figure 7: Metformin inversely modulates mir-33a and its targets. The heat map shows opposite regulation of the microRNA-
33a and its gene targets (c-MYC, IRS-2)(Normalized intensity values) in metformin treated ALDHbright cells. Triplicate experiments. 
Figure 8: Representative working model. Metformin modulates the microRNA profile of ALDHbright cells thereby impacting on their 
metabolic properties. This makes the ALDHbright cells more similar to the ALDHlow cells and affect chemoresistance of the tumor, potentially 
reducing its relapse. Metformin proposed action may take place either before or in conjunction with chemotherapy. Dashed arrows indicate 
speculated actions of the drug.
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due to a mir-33a-dependent modulation of c-MYC levels 
[15]. In facts, C-MYC is a central modulator of cancer cell 
metabolism, alone or in cooperation with HIF-1α [17, 18]. 
To assess whether a similar mechanism would operate in 
the ALDHbright cancer cells as well, we evaluated the levels 
of microRNA 33a and its target c-MYC in ALDHbright 
cells, treated with vehicle or metformin, respectively. 
By performing quantitative PCR, we observed a strong 
modulation of mir-33a levels which anti-correlated with 
those of c-MYC. Additionally, we found that the levels of 
IRS-2, a central modulator of insulin signalling in normal 
and cancer cells and a target of microRNA33a as well [19] 
were modulated by metformin (Fig. 7). A working model 
that generally resumes the collected observations is shown 
in Fig. 8 (Fig. 8).
DISCUSSION
We have recently shown that a complex interplay of 
microRNA modulation and pathway signalling underlies 
the anticancer effects of metformin, an anti-diabetic 
agent which epidemiological evidence suggest to play 
an important role in cancer prevention [15, 20, 21]. With 
the aim of detailing our previous studies, in this work we 
have studied the metabolic changes taking place in breast 
ALDHbright cells, the main cell subpopulation responsible 
for the chemoresistance of breast tumors. This because 
understanding the metabolism of chemoresistant cell 
subpopulations may aid the identification of the basic 
mechanism sustaining their chemoresistance, a major 
factor shaping the prognosis of breast cancer patients. 
Our experimental systems included three breast cancer 
cell lines, differing for histological origin and growth 
rate. Indeed, our metabolomics analysis identified the cell 
line specificity as a major determinant of the differences 
between the samples, thus confirming the efficiency 
of the approach. Despite this, the OPLS-DA analysis 
allowed us to focus on the differences between vehicle- 
and metformin- treated ALDHbright cells. First, we found 
that the metabolic profile of the purified ALDHbright cell 
subpopulations was significantly different from that of the 
ALDHlow cells. When focusing on the metabolic changes 
induced by metformin treatment and common to the 
ALDHbright cells from all the cell lines examined (MCF-
7, BT-474, SUM-159-ALDHbright cells), an increase in 
glucose and glutamine uptake and lactate production as 
well as the decrease in pyroglutamate production were 
observed upon metformin treatment. Interestingly, a 
reduced excretion of pyroglutamate from the metformin-
treated cells indicated reduced levels of intracellular 
glutathione. This is in line with recent findings showing 
that metformin affected the glutathione (GSH) homeostasis 
of breast cancer cells, with the reduced glutathione 
biosynthesis correlating with a blockage of de novo 
purine/pyrimidine synthesis[22]. Our observations suggest 
that negative modulation of the glutathione homeostasis 
in the ALDHbright cell subpopulations may underlie the 
anticancer action of metformin. In facts, higher levels of 
intracellular glutathione have been described in chemo- 
and radio-resistant “cancer stem cell –like (CSCs)” cell 
subpopulations derived from MMTV-WNT1 breast 
tumors[23]. Additionally, this correlated with a broad 
modulation of the mRNA levels of the genes involved in 
the glutathione metabolism. We speculate that metformin 
treatment may reduce the glutathione pool in the breast 
ALDHbright cell subpopulations thereby abating their 
resistance to therapy. Interestingly, recent findings suggest 
that blockage of c-MYC downstream effectors affected 
glycolysis and glutathione biosynthesis in MYC-driven 
mouse lymphoma models[24]. In line with this, we have 
found that metformin downregulated the c-MYC levels 
in ALDHbright cells, possibly by upregulating the mir-
33a levels. C-MYC activation in ALDHbright cells may 
strongly cooperate with the activation of HIF-1 metabolic 
effectors, such as several glycolytic enzymes [3, 25, 26]. 
The latter phenomenon was observed by our 1H-NMR 
analysis. Additionally, IRS-2 is downregulated by 
metformin and, like for c-MYC, this inversely correlated 
with the levels of mir-33a in the metformin treated cells. 
IRS-2 is an important modulator of aerobic glycolysis in 
mouse mammary cancer cells [27]. Notably, modulation 
of c-MYC and IRS-2 mRNA levels was already shown 
by us in unfractionated, metformin treated breast cells 
lines [15]. What we believe is remarkable here is that 
the treatment with metformin drastically reduced the 
metabolic difference between ALDHbright and ALDHlow 
cells. A very similar effect was observed on the microRNA 
expression profile of metformin treated ALDHbright and 
ALDHlow cells. This is very interesting since the ALDHlow 
cells represent the chemosensitive fraction of solid tumors 
and it indicates the potential of metformin for metabolic 
reprogramming of chemoresistant cell subpopulations. 
This represents a further mechanism of cancer interference 
by this promising compound (Fig. 8). 
METHODS
Reagents.
Metformin (1,1-Dimethylbiguanide-hydrochloride) 
Cisplatin and and Doxorubicin-hydrochloride were 
dissolved according to the manufacturer’s instructions. 
(Sigma, St Louis, MO, USA)
Cell culture conditions. 
MCF-7 and BT-474 breast cancer cell lines were 
grown in DMEM/F12 supplemented with 10% non-heat 
inactivated FBS (Invitrogen-GIBCO, Carlsbad, CA, 
USA); the MCF10A and SUM159 cells were grown in 
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DMEM/F-12 supplemented with 5% FBS, Insulin 5µgr/
ml (SIGMA) and Hydrocortisone 0.5 µgr/mL (SIGMA). 
ALDH activity assay. 
ALDH activity was detected by FACS CALIBUR 
instrument (BD Biosciences, Franklin Lakes, New Jersey, 
USA). ALDEFLUOR kit (Stem Cell Technologies, 
Vancouver, Canada) was used according to the 
manufacturer’s instructions. ALDHbright cells were defined 
as the cells that displayed greater fluorescence compared 
with a control staining reaction containing the ALDH 
inhibitor, DEAB (diethylaminobenzaldehyde). The 
analysis was performed by using FlowingSoftware 2.0 
(Cell Imaging Core, University of Turku, Finland).
Cell Sorting. 
ALDEFLUOR kit was used according to the 
manufacturer’s instructions to detect the ALDH activity. 
Cells were filtered through a 40µM mesh to obtain a 
single cell suspension . Cell sorting was performed with a 
MoFLO cell sorter (DAKOCYTOMATION ,Fort Collins, 
Colorado, USA)
Cell Viability.
The SYTOX® Orange Dead Cell Stain( Invitrogen-
Molecular Probes, Carlsbad, CA, USA) was used to assess 
cell viability as per manufacturer’s instructions.
Clonogenic assays.
The breast cancer cell lines were grown to 70% 
confluence and pulse treated with the indicated drugs. 
16hrs later, cells were detached(Accutase-GIBCO) and 
seeded at 500-1500 cells/well into 6-well dishes (Corning-
Costar, Tewksbury, MA, USA) in drug-free media. Fresh 
medium (25%) was added every three days. Colonies were 
stained with crystal violet (SIGMA) and colonies (>50 
cells) counted after 7- 14 days
NMR sample preparation
Extracellular metabolites were separated by 
ultrafiltration (AMICON) before methanol/chloroform/
water extraction (2/2/1.8) to extract non polar 
metabolites[28, 29].
1H-NMR Spectroscopy. 
For 1H-NMR analysis, polar extracts were dissolved 
in 600μl of 1 mM TSP [(trimethylsilyl)-propionic-
2,2,3,3-d4 acid] and 10 mM NaN3 solution in D2O 0.1 
M phosphate buffer (pH=7.4), while non-polar extracts 
were dissolved in 600μl of CDCl3 containing 0.03% TMS 
(tetramethylsilane) / CD3OD solution (2:1, v/v). 
All 2D 1H J-resolved (JRES) NMR spectra 
were acquired on a 500 MHz DRX Bruker Avance 
spectrometer (Bruker, Germany) using a double spin echo 
sequence with 8 transients per increment for a total of 32 
increments. These were collected into 16k data points 
using spectral widths of 6 kHz in F2 and 40 Hz in F1. 
There was a 3.0 s relaxation delay. The water resonance 
was suppressed using presaturation. Each FID was Fourier 
transformed after a multiplication with sine-bell window 
functions in both dimensions. JRES spectra were tilted 
by 45°, symmetrised about F1, referenced to TSP at δH 
= 0.0 ppm and the proton-decoupled skyline projections 
(p-JRES) exported using Bruker’s XWIN-NMR software. 
Metabolites were identified using an in-house NMR 
database and literature data and confirmed by 2D homo- 
and heteronuclear NMR spectroscopy. 1H-NMR spectra 
pre-processing. All p-JRES exported were aligned and 
then reduced into spectral bins with widths ranging from 
0.01 to 0.02 ppm by using the ACD intelligent bucketing 
method (ACD/Labs, Canada) that sets the bucket divisions 
at local minima (within the spectra) to ensure that each 
resonance is in the same bin throughout all spectra. After 
this procedure, the 1H spectra were divided into n bins. 
The area within each spectral bin was integrated to yield 
a n-component vector, where each component value was 
represented by the integral value corresponding to the 
specific spectral bin. To compare the spectra, the integrals 
derived from the bucketing procedure were normalized 
to the total integral region, following exclusion of bins 
corresponding to solvent (residual water/HDO, δ4.76-
4.82 ppm; CDCl3, δ 7.45-7.50 ppm; CD3OD,δ 3.33-3.37 
ppm), TSP, TMS (δ -0.5-0.5 ppm) and metformin peaks 
(δ3.03-3.06 ppm). Data from extracellular media were 
expressed in terms of net balances at 0 and 24hrs. This to 
establish consumption (c) or production (p) of the selected 
metabolites in time.
Univariate statistical data analysis. 
Analysis of variance (ANOVA) is a technique 
for analysing experimental data in which one or more 
(or dependent) variables are measured under various 
conditions, identified by one or more classification 
variables. The response is separated into variation 
attributable to differences between the classification 
variables and variation attributable to random errors. 
An analysis of variance constructs tests to determine the 
significance of the classification effects. A typical goal is 
to compare means of the response variables for various 
combinations of the classification variables (interaction 
effects). 
In our study, we considered metabolite consumption 
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and production as a dependent variable while type of 
subpopulation, type of cell line and treatment effect 
as the classification variables. The resulting data was 
used as input for univariate and multivariate analysis 
Principal Component Analysis (PCA)[30] and Orthogonal 
Projections to Latent Structures-Discriminant Analysis 
(OPLS-DA)[31]. PCA and OPLS-DA were conducted 
using SIMCA-P+ version 12 (Umetrics, Umea, Sweden). 
Principal Component Analysis.
Principal Component Analysis (PCA) is a projection 
method used for exploiting the information embedded in 
multidimensional data sets. The data is reduced to a few 
latent variables (or principal components) collecting the 
information implicit in the original variables correlation 
structure. The presence of correlations between the original 
variables allows for the reduction of dimensionality of 
the data set in the new space without noticeable loss of 
information. The extracted components (PCs) are each 
orthogonal and ordered in terms of percentage of explained 
variation, with the first components collecting the 
‘signal’ (correlated) portion of information, while minor 
components can be considered as ‘noise’ components. 
Because the principal components are, by construction, 
orthogonal to each other, a clear-cut separation of the 
different and independent features characterizing the 
data set is made possible. Each statistical unit is assigned 
a score relative to each extracted component, while the 
correlation coefficient between each original variable 
and extracted components (loading) gives a meaning to 
the PCs. The output from the PCA analysis consists of 
score plots, which provide an indication of the differences 
between the classes in terms of metabolic similarity, and 
loading plots. These loading plots give an indication of 
which metabolite net balances are important with respect 
to the classification obtained in the score plots.
Orthogonal projections to latent structures 
discriminant analysis (OPLS-DA)
Orthogonal projections to latent structures 
discriminant analysis (OPLS-DA) is a supervised 
pattern recognition technique widely used in the field 
of metabolomics to interpret large multivariate data sets 
describing differences between the groups under study in 
a straightforward and accurate way.
OPLS-DA separates the systematic variation in 
the matrix X (spectroscopic data) into two parts, one 
linearly related (variation of interest) to the matrix Y (the 
classification variables) and one orthogonally related (so 
called orthogonal variation or structured noise) to the 
matrix Y. This partitioning of the X-data improved the 
interpretation of the model. 
In our study, we considered consumption and 
production of metabolites as X matrix and type of 
subpopulation as Y matrix. The influence of the original 
variables on the obtained model was determined using 
loading values.
RNA processing and hybridization
Total RNA from the FACS sorted ALDHbright 
and ALDHlow cells (98 ± 0.4% and 97 ± 1.4% purity, 
respectively, as assessed by re-FACS) was extracted by 
TRI Reagent lysis reagent (Life Technologies-AMBION 
Carlsbad, CA, USA) according to the manufacturer’s 
instructions. The microRNA Complete Labeling and 
Hyb Kit (AGILENT Santa Clara, CA, USA) was used to 
generate fluorescent miRNA, according to manufacturer’s 
instructions. Scanning and image analysis were performed 
using the Agilent DNA Microarray Scanner (P/N 
G2565BA). Feature Extraction Software (V-10.5) was 
used for data extraction from raw microarray image files 
using the miRNA_105_Dec-09FE protocol.
Analysis of microRNA expression. 
Pearson’s correlation coefficient was calculated in 
order to assess quality of replicates. ANOVA test α=5%) 
was performed to assess statistical significance of the 
observed differences in microRNA profiling (Fig.S2). 
Preprocessing.
 The signal of 851 human miRNAs was processed 
by MATLAB (The MathWorks Inc.) in in house-built 
routines. All background-subtracted intensity values lower 
than 1 were considered below detection and thresholded to 
1. The arrays were quantile-normalized forcing each slide 
to assume the same mean distribution and log2-trasformed.
Feature selection. Clusters in data were identified 
by unsupervised Hierarchical Clustering and Principal 
Component Analysis. A permutation t-test and bootstrap 
test were used to select deregulated miRNAs after 
treatment. A false discovery rate (FDR) procedure was 
also applied for multiple comparisons. All tests were 
two-tailed and considered significant if both p-value and 
q-value (FDR) were less than 0.05.
miRNA-pathway assignment prediction.
 A list of predicted miRNAs in pathway 
experimentally identified from metabolomics was 
extracted using miRWalk (http://www.umm.uni-
heidelberg.de/apps/zmf/mirwalk/)[32]. Predicted miRNAs 
with significant modulation of the signal after treatment 
in the array experiment were considered for further 
investigations.
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cDNA synthesis and gene expression. 
The first-strand cDNA was synthesized according 
to manufacturer’s instructions (M-MLV Reverse 
Transcriptase, Life Techonlogies). Gene expression was 
measured by real-time PCR using the FAST SYBRGreen 
master mix (Applied Biosystems, Foster City, CA, USA) 
on a StepOne instrument (Applied Biosytems). 
Sequences of the Q-PCR primers are: 
IRS-2 Fw: ACGCCAGCATTGACTTCTTGT, 
Rv :GCCAGACAGATCTTCACTCTTTCA; 
ACTIN Fw: GGCATGGGTCAGAAGGATT, Rv: 
CACACGCAGCTCATTGTAGAAG; C-MYC 
Fw: CTCCTGGCAAAAGGTCAGAG, Rv: 
TCGGTTGTTGCTGATCTGTC.ACTIN was used as 
endogenous control
Statistical Analysis. 
Generally, Student’s t-test was used to assess 
significance of the data generated except where otherwise 
specified.
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